中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 1
Jan.  2023
Turn off MathJax
Article Contents

Expanding the treatment of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2023.01.001
More Information
  • Corresponding author: ZHUANG Hui, zhuangbmu@126.com
  • Received Date: 2022-11-18
  • Published Date: 2023-01-20
  • Among chronic hepatitis B patients eligible for treatment, only 5% have received antiviral therapy worldwide. The strictness of treatment criteria in current guidelines is one of the contributing factors for the low treatment rate of patients with chronic hepatitis B, and expanding the treatment criteria for chronic hepatitis B established in current guidelines may reduce disease burden. Universal hepatitis B vaccination, universal screening, and treatment of all HBV DNA-positive patients will help to achieve the goal of HBV elimination by 2030 proposed by the World Health Organization.

     

  • loading
  • [1]
    SORIANO V, ALVAREZ C, EDAGWA B, et al. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis[J]. Int J Infect Dis, 2022, 114: 45-50. DOI: 10.1016/j.ijid.2021.10.052.
    [2]
    World Health Organization. Global hepatitis report, 2017[R]. Geneva: World Health Organization, 2017.
    [3]
    World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030[R]. Geneva: World Health Organization, 2022.
    [4]
    Polaris Observatory HBV Collaborators[EB/OL]. [2022-11-10]. https://cdafound.org/dashboard/polaris/dashboard.html.
    [5]
    SINN DH, KIM SE, KIM BK, et al. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria[J]. J Viral Hepat, 2019, 26(12): 1465-1472. DOI: 10.1111/jvh.13185.
    [6]
    SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
    [7]
    TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
    [8]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
    [9]
    PAPATHEODORIDIS GV, LAMPERTICO P, MANOLAKOPOULOS S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review[J]. J Hepatol, 2010, 53(2): 348-356. DOI: 10.1016/j.jhep.2010.02.035.
    [10]
    PAPATHEODORIDIS GV, IDILMAN R, DALEKOS GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B[J]. Hepatology, 2017, 66(5): 1444-1453. DOI: 10.1002/hep.29320.
    [11]
    CHEN YC, CHU CM, LIAW YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology, 2010, 51(2): 435-444. DOI: 10.1002/hep.23348.
    [12]
    YUEN MF, WONG DK, FUNG J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma[J]. Gastroenterology, 2008, 135(4): 1192-1199. DOI: 10.1053/j.gastro.2008.07.008.
    [13]
    CHOI H, TONTHAT A, JANSSEN H, et al. Aiming for functional cure with established and novel therapies for chronic hepatitis B[J]. Hepatol Commun, 2022, 6(5): 935-949. DOI: 10.1002/hep4.1875.
    [14]
    WONG RJ, KAUFMAN HW, NILES JK, et al. Simplifying treatment criteria in chronic hepatitis B: Reducing barriers to elimination[J]. Clin Infect Dis, 2022. DOI: 10.1093/cid/ciac385.[Onlineaheadofprint]
    [15]
    TONG MJ, PAN CQ, HAN SB, et al. An expert consensus for the management of chronic hepatitis B in Asian Americans[J]. Aliment Pharmacol Ther, 2018, 47(8): 1181-1200. DOI: 10.1111/apt.14577.
    [16]
    RAZAVI-SHEARER D, ESTES C, GAMKRELIDZE I, et al. Cost-effectiveness analysis of treating all HBsAg+ individuals in the United States[J]. Hepatology, 2021, 74(Suppl 1): 22A.
    [17]
    LIM YS, AHN SH, SHIM JJ, et al. Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis[J]. Aliment Pharmacol Ther, 2022, 56(3): 519-528. DOI: 10.1111/apt.17052.
    [18]
    Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
    [19]
    TOY M, HUTTON D, HARRIS AM, et al. Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States[J]. Clin Infect Dis, 2022, 74(2): 210-217. DOI: 10.1093/cid/ciab405.
    [20]
    RAMRAKHIANI NS, CHEN VL, LE M, et al. Optimizing hepatitis B virus screening in the United States using a simple demographics-based model[J]. Hepatology, 2022, 75(2): 430-437. DOI: 10.1002/hep.32142.
    [21]
    SU S, WONG WC, ZOU Z, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation[J]. Lancet Glob Health, 2022, 10(2): e278-e287. DOI: 10.1016/S2214-109X(21)00517-9.
    [22]
    WENG MK, DOSHANI M, KHAN MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: Updated recommendations of the advisory committee on immunization practices-United States, 2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(13): 477-483. DOI: 10.15585/mmwr.mm7113a1.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)

    Article Metrics

    Article views (2536) PDF downloads(426) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return